Organic Active Ingredients TRIZ Cases

Aramchol inhibits TGF-beta signaling and reverses established cirrhosis scores without the toxicity of conventional therapies.

Replacing biphenyl cores with phenyl triazole structures improves water solubility and safety while maintaining strong MLL1 enzymatic inhibition.

Optimized ethanol and propylene glycol solvents maintain thiotepa purity, eliminating reconstitution steps that cause instability.

Direct ASM inhibitors using triazolopropane-diol derivatives reduce Aβ plaques and nerve inflammation without adverse side effects.

Bifunctional degraders target HPK1 via ubiquitin ligase recruitment, boosting anti-tumor immunity where checkpoint inhibitors show low response rates.

Acid treatment of tea leaves prevents oxidation and increases epigallocatechin gallate content compared to traditional processing.

Novel pyrrolo[2,3-b]pyridine compounds inhibit LRRK2 kinase activity with high potency and selectivity.

Cyclic tetrapeptides act as selective kappa opioid receptor antagonists to treat drug addiction.

Acellular pro-tolerogenic preparations enriched in specific miRNAs increase regulatory T cell ratios to prevent graft rejection without chronic toxicity.

Synthetic peptides replace invasive blepharoplasty by improving skin firmness, reducing under-eye bags without surgical risks.

Dissolving and precipitating polyesters removes metal contaminants, eliminating burst effects and lag times in drug delivery.

An inert biodegradable sheath prevents tissue interaction while allowing uniform solvent access, ensuring safe and effective drug concentrations.

A cyclohexene compound inhibits influenza neuraminidase with high potency.

Pyrazolyl pyrimidinylamine compounds resolve off-target effects by selectively inhibiting CDK2, reducing retinoblastoma protein phosphorylation.

Adjustable BSBM3 dosing minimizes cytokine release syndrome while maintaining anti-tumor efficacy in cancer treatment.

AT-1 receptor antagonists block maternal antibodies from inhibiting neural progenitor cells, reversing impaired neurogenesis.

Novel pyridazine compound inhibits hepatitis C virus replication, reducing adverse effects and treatment duration compared to interferon therapies.

Alpha interferon treatment reduces tissue damage and viral replication in H7N9 hosts, bypassing neuraminidase inhibitor resistance.

Mitofusin inhibitors bind the HR2 domain to disrupt oligomers, inducing fission and caspase activation to treat diseases linked to imbalanced dynamics.

Amphiphile-polymer particles encapsulate therapeutic payloads within a water-insoluble core and amphiphilic shell to achieve sustained release.

Administering miR-122, miR-15b, and miR-155 activates natural killer cells to resolve ineffective conventional cancer therapies.

Combining Radix et Rhizoma Notoginseng total saponins with aspirin creates a composite pharmaceutical preparation.

Supercritical carbon dioxide sterilizes and decellularizes extracellular matrix tissue, avoiding conventional methods that damage native properties.

A hydrophobic petrolatum carrier bridges the stratum corneum barrier to deliver hydrophilic actives with poor water solubility.

A cytisine formulation uses a nitrite scavenger to prevent N-nitrosocytisine formation during storage.

Disulfide-linked TAT dimers enable efficient cytosolic protein delivery by resolving the trade-off between endosomal escape and cell viability.

Specific alkyl and aryl substituents on the purine core enhance therapeutic efficacy while maintaining structural simplicity to treat various cancers.

A spirulina, vitamin C, and vitamin D formulation delivers antiviral and anti-inflammatory action through synergistic multi-stage treatment.

Modified polynucleic acids inhibit mutant and wild-type EGFR expression with high specificity.

Thiazole-substituted benzamides selectively inhibit P2X3 receptors, avoiding taste perception alterations common with non-selective antagonists.

Characterizing multiple solid state forms of a PPARδ agonist via XRPD and DSC to resolve formulation complexity while enhancing metabolic efficacy.

Monohydrate crystalline form of azaazulene kinase inhibitor resolves solubility variability through controlled dissolution and evaporation.

Segmented guide RNAs with 5' extensions and stem loops improve gene editing efficiency while maintaining synthesis simplicity.

A neuroactive steroid composition utilizes cyclodextrins to enable rapid parenteral delivery for treating central nervous system disorders.

Parameter changes and seeding produce pure Form A, avoiding hydrate impurities.

Lixisenatide reduces postprandial glucose and glucagon levels, addressing insufficient glycemic control in high BMI pediatric patients with type 2 diabetes.

A pharmaceutical composition uses siRNA to inhibit tumor formation and metastasis in liver cancer.

Luteolin reduces inflammatory markers and disease volume while minimizing side effects from conventional high-dose therapies.

A melphalan flufenamide formulation incorporates gamma-cyclodextrin to enhance aqueous solubility and stability.

Segmented Bcl-2 inhibitors overcome weak binding affinities of non-peptide molecules to induce apoptosis in cancer cells.

Specific dosing ranges and continuous monitoring minimize cytokine release syndrome while treating relapsed large B-cell lymphoma.

Integrates hypocretin/orexin receptor antagonists with opioids to block addiction-associated neural changes while maintaining effective pain relief.

Antifungal wipe replaces alcohol solvents with glycerin carriers to eliminate skin irritation while maintaining treatment efficacy.

Oral substituted benzoxazoles resolve bleeding risks and latency periods associated with heparin and vitamin K antagonists.

Combines anti-CD79b immunoconjugates with Bcl-2 inhibitors and anti-CD20 antibodies to overcome relapse refractoriness in lymphoma patients.

Inhibiting PTPN22 reduces autoreactive B cell frequency without depleting the entire immune system, preventing relapse from defective tolerance mechanisms.